The American Porphyria Foundation proudly announces our new office location!
Effective June 1, 2018, we will be located at:
American Porphyria Foundation
4915 St. Elmo Avenue, Suite 105
Bethesda, MD 20814
This move lands the APF near our nation’s capital – and down the road from the NIH, the FDA, Capitol Hill and multiple national rare disease organizations. What it does not change is our relentless focus on impacting the lives of all individuals and families that live with Porphyria. We thank you for your tremendous support and look forward to serving you from our new home.
Porphyria Cutanea Tarda (PCT) TRIAL
Participants are needed for an ongoing clinical trial for patients with PCT to study treatment with Harvoni, which is a prescription drug used to treat adults with chronic Hepatitis C. In this study all patients with PCT will be given a standard dose of Harvoni and will be monitored for two years.
If a participant is eligible, he/she will be asked to visit the study site once every month over the course of one year, and then once every 3 months for an additional year. At these visits the study doctors will check in with the participant and both blood and urine samples will be taken. ALL LABS and ALL MEDICATION are provided free of charge.
This is a wonderful opportunity for you to not only change your health, but to help change the health of others with PCT! Please contact Edrin Williams at the APF on 1-866-APF-3635 to connect with a research coordinator.